Doctor with Mammography


that sets a facility apart

EOS imaging is a global medical device company that develops and markets advanced imaging and imaged-based solutions for diagnosing, treating and monitoring the most common musculoskeletal pathologies.

EOS imaging logo.jpg
Connecting imaging to care
  • Nobel Prize winning unique 3D Imaging Technology.

  • Unique combination of low dose 2D/3D imaging technology, software.

  • For musculoskeletal pathologies and orthopedic surgical care.

  • Available along the entire care pathway, from diagnosis to long term follow-up.


Are you looking to differentiate your practice? 

View our webinar to hear how Dr. John Asghar, spine surgeon at the Cantor Spine Center and the Paley Orthopedics and Spine Institute, is using 2D/3D imaging solutions for degenerative spine management.

EOS System
  • The EOS system provides low dose, full body, stereo-radiographic images of your patient in a functional position.

  • The unique biplanar design and vertical scanning allows the acquisition of full body with precise 2D and 3D measurements, helping clinicians to better visualize mechanisms between the spine, hip, and knee, enhancing patient treatment across all stages of care. 

  • The EOS system introduces a fifth modality to reduce patient radiation dose for a wide range of patients providing an exceptional image contrast. 

Clinical Benefits
  • Comprehend compensation mechanisms between the spine, hip and knee thanks to full body, weight-bearing images.

  • Calculate precise 2D and 3D measurements, free from magnification and stitching bias.

  • Improved diagnostics due to high image quality and over 65,000 grey levels for excellent contrast. 


Facility-wide Efficiency
  • Capture frontal and lateral, full body images in less than 20 seconds for adults and 15 seconds for children.

  • Complete an exam in under 4 minutes, even for complex spine or full body.

  • Maximize patient throughput with up to 100 complex exams per day.

  • Facilitate the process to image disabled patients with the EOS Radiolucent Chair.

Dose Reduction
  • Patient’s radiation dose decreased by 50% compared to a DR system and 85% compared to a CR system.

  • Substitution of specific CT exams with an EOS exam to reduce the patient’s radiation dose by 95%.

  • Micro Dose protocol for a full spine exam (frontal and lateral) at a dose that’s equivalent to only a week’s worth of natural radiation.

2_Full_Body with 3D skeleton.jpg
white background 3D with PTH - White Bac

  • EOS imaging designs, develops and markets EOS, a unique and innovative medical imaging system dedicated to osteo-articular and orthopedic pathologies, as well as its associated software and services.

  • The EOS platform is a unique combination of low dose 2D/3D imaging technology, software and services that add value to each step of the musculoskeletal patient care pathway. From diagnosis to long term follow-up, an EOS exam provides full body, 2D/3D images and patient-specific data sets to plan and control surgeries based on 3D anatomical models of the patient in a weight-bearing position.

  • EOS represents a major advancement in the field of osteo-articular pathologies, which affect a large number of patients – particularly children, adolescents, and the elderly.

  • EOS allows for simultaneous generation of two stereo-radiographic images – frontal and lateral – of the patient’s body in a functional position (standing or seated). Additionally, Patient’s radiation dose decreased by 50%* compared to a DR system, 85%* compared to a CR system and 95%* compared to computed tomography (CT). The Micro Dose option further reduces radiation levels and allows for a full spine exam (frontal and lateral) at a dose equivalent to only a week’s worth of natural radiation*. This feature is especially important for patients with disorders that require frequent scanning throughout treatment.

  • The EOS system is able to complete the entire medical exam in less than 4 minutes, with the actual scanning process itself lasting less than 20 seconds.

  • The accompanying sterEOS workstation enables to create patient-specific 3D models, calculate over 100 clinical parameters6 automatically and generate customizable patient reports.

Early detection is extremely important for managing cancer especially in developing countries. 

We advise national and international missions on mass screening and diagnosis to detect early stage cancer.

Our Breast cancer screening is a unique Mobile Project, that uses Artificial Intelligence and latest technologies to investigate breast cancer amongst large sections of population in rural and semi-rural areas at their doorsteps.


Since the late 1980s, organised breast mammography screening programmes have been introduced in more and more countries across the world, based on the results of 8 large randomised trials. The aim of mammography screening is to detect breast cancer as early as possible, primarily in order to reduce the number of breast cancer deaths but also to reduce the severity of the disease and the use of heavy cancer treatments (and associated anxiety).

These programmes have always used a “one size fits all” strategy whereby women in a target age group (typically between 50-69 years old) are invited for a mammogram (2 incidences bilateral x-ray taken of their breast) every 2 or 3 years. This approach has demonstrated benefits (reduction of breast cancer specific mortality by 20%). However, it also comes with certain side effects, such as false positive findings, overdiagnosis and overtreatment – meaning treatment of indolent cancers (ones that would never have caused problems during a woman’s lifetime because they evolve very slowly), and a small lifetime risk of radiation-induced cancer. Furthermore, the current mammography screening’s sensitivity is not perfect; and the mortality impact not as high as could be expected.

A promising approach to improve mammography screening is personalized, individual risk-based screening.

In the current strategy, all invited women are treated the same. But women are not all the same: each woman has her own individual risk of developing breast cancer, depending on many factors like genetic factors, lifestyle, or hormonal exposure.

Recent scientific advances have largely improved our understanding of breast cancer genetics and other risk factors. We now have accurate risk assessment tools and sufficient knowledge to investigate the advantages of using a new screening approach based on individual risk estimation of breast cancer: this is the goal of Jona Breast Screening.